ArticleInternational journal of nanomedicine2017
Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Smart Antidiabetic Nanomedicine: A Revolutionized Therapeutic Approach for Treatment of Diabetes Mellitus.Bioengineering (Basel, Switzerland) · 2025Review
- A Spotlight on PLGA-based Nanoparticles: Pioneering a New Era in the Therapeutics of Cardiovascular Disorders.Current pharmaceutical design · 2025Review
- Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction.Molecules (Basel, Switzerland) · 2024Review
- Nanoparticles as a Novel Platform for Cardiovascular Disease Diagnosis and Therapy.International journal of nanomedicine · 2024Review
- Nanomedicines for cardiovascular disease.Nature cardiovascular research · 2023Review
- Liraglutide, a TFEB-Mediated Autophagy Agonist, Promotes the Viability of Random-Pattern Skin Flaps.Oxidative medicine and cellular longevity · 2021Article
- Nanoparticles: Promising Tools for the Treatment and Prevention of Myocardial Infarction.International journal of nanomedicine · 2021Review
- Biomaterials Loaded with Growth Factors/Cytokines and Stem Cells for Cardiac Tissue Regeneration.International journal of molecular sciences · 2020Review
- Cardiovascular effects of antiobesity drugs: are the new medicines all the same?International journal of obesity supplements · 2020Review
- Mesenchymal stem cells combined with liraglutide relieve acute lung injury through apoptotic signaling restrained by PKA/β-catenin.Stem cell research & therapy · 2020Article
- Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease.Frontiers in bioengineering and biotechnology · 2020Review
- Incremental effect of liraglutide on traditional insulin injections in rats with type 2 diabetes mellitus by maintaining glycolipid metabolism and cardiovascular function.Experimental and therapeutic medicine · 2019Article
- Liraglutide Increases VEGF ExpressionFrontiers in pharmacology · 2019Article
- Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration.Stem cells international · 2018Review
- Triphenylphosphonium and D-α-tocopheryl polyethylene glycol 1000 succinate-modified, tanshinone IIA-loaded lipid-polymeric nanocarriers for the targeted therapy of myocardial infarction.International journal of nanomedicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The local, intramyocardial injection of proteins into the infarcted heart is an attractive option to initiate cardiac regeneration after myocardial infarction (MI). Liraglutide, which was developed as a treatment for type 2 diabetes, has been implicated as one of the most promising protein candidates in cardiac regeneration. A significant challenge to the therapeutic use of this protein is its short half-life in vivo. In this study, we evaluated the therapeutic effects and long-term retention of liraglutide loaded in poly(lactic-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.